ClinicalTrials.gg

Program

AND017

A development code. Also written as “AND017 capsules”, “AND017 capsules TIW” and “AND017 capsules QW”.

Its studies are mostly in Anemia · Thalassemia · Myelodysplastic Syndromes, led by Kind Pharmaceuticals.

Furthest: phase 3, since Mar 17, 202610 company-led studies, 6 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Kind Pharmaceuticals106 open or runningphase 3since Mar 17, 2026Jan 13, 2021Dec 2026phase 2 · NCT06302491

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2021First studies: 2 phase 1 studies in Healthy VolunteersFirst studyNCT04712500, NCT04751539
  2. Apr 21, 2021Phase 2 study in Renal AnemiaNCT05035641 · 113 enrolled · United States, China
  3. Feb 22, 2022Phase 2 study in Renal AnemiaNCT05265325 · 175 enrolled · United States, China
  4. Mar 22, 20234 phase 2 studiesNCT06304103, NCT06302491, NCT06075043 and 1 more
  5. Mar 17, 20262 phase 3 studies in AnemiaPhase 3 reachedNCT07487727, NCT07494409

Ahead

  1. Dec 2026Primary completion: phase 2 study in Myelodysplastic SyndromesNCT06304103
  2. Dec 2026Primary completion: phase 2 study in β -ThalassemiaNCT06302491
  3. Dec 1, 2026Primary completion: phase 3 study in AnemiaNCT07487727
  4. Dec 2027Primary completion: phase 2 study in Chemotherapy Induced AnemiaNCT06075030

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07494409Anemia · China3RecruitingOct 30, 2026300
NCT07487727Anemia · China3RecruitingDec 1, 2026240
NCT06304103Myelodysplastic Syndromes · China2RecruitingDec 202663
NCT06302491β -Thalassemia · China2RecruitingDec 202664
NCT06075043Cancer-Related Anemia2Not yet recruitingMay 202836
NCT06075030Chemotherapy Induced Anemia2Not yet recruitingDec 202736
NCT05265325Renal Anemia · United States, China2CompletedFeb 29, 2024175
NCT05035641Renal Anemia · United States, China2CompletedJul 5, 2023113
NCT04751539Healthy Volunteers · Australia1CompletedFeb 11, 201978
NCT04712500Healthy Volunteers · China1CompletedAug 16, 202014

How it is read

Names in the registry

  • “AND017”, 6 entries
  • “AND017 capsules”, 2 entries
  • “AND017 capsules TIW”, 1 entry
  • “AND017 capsules QW”, 1 entry
  • “AND017 single dose”, 1 entry

Codes read as this program: AND017.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.